podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 20/22 Podcast
  4. Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients
Introduction: Circulating microRNAs (miRNAs) are easily accessible
and have already proven to be useful as prognostic markers in
cancer patients. However, their origin and function in the
circulation is still under discussion. In the present study we
analyzed changes in the miRNAs in blood plasma of head and neck
squamous cell carcinoma (HNSCC) patients in response to
radiochemotherapy and compared them to the changes in a cell
culture model of primary HNSCC cells undergoing simulated
anti-cancer therapy. Materials and methods: MiRNA-profiles were
analyzed by qRT-PCR arrays in paired blood plasma samples of HNSCC
patients before therapy and after two days of treatment. Candidate
miRNAs were validated by single qRT-PCR assays. An in vitro
radiochemotherapy model using primary HNSCC cell cultures was
established to test the possible tumor origin of the circulating
miRNAs. Microarray analysis was performed on primary HNSCC cell
cultures followed by validation of deregulated miRNAs via qRT-PCR.
Results: Unsupervised clustering of the expression profiles using
the six most regulated miRNAs (miR-425-5p, miR-21-5p, miR-106b-5p,
miR-590-5p, miR-574-3p, miR-885-3p) significantly (p = 0.012)
separated plasma samples collected prior to treatment from plasma
samples collected after two days of radiochemotherapy. MiRNA
profiling of primary HNSCC cell cultures treated in vitro with
radiochemotherapy revealed differentially expressed miRNAs that
were also observed to be therapy-responsive in blood plasma of the
patients (miR-425-5p, miR-21-5p, miR-106b-5p, miR-93-5p) and are
therefore likely to stem from the tumor. Of these candidate marker
miRNAs we were able to validate by qRT-PCR a deregulation of eight
plasma miRNAs as well as miR-425-5p and miR-93-5p in primary HNSCC
cultures after radiochemotherapy. Conclusion: Changes in the
abundance of circulating miRNAs during radiochemotherapy reflect
the therapy response of primary HNSCC cells after an in vitro
treatment. Therefore, the responsive miRNAs (miR-425-5p, miR-93-5p)
may represent novel biomarkers for therapy monitoring. The
prognostic value of this exciting observation requires confirmation
using an independent patient cohort that includes clinical
follow-up data.

Weitere Episoden

Persistent nasal methicillin-resistant staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome

Persistent nasal methicillin-resistant staphylococcus aureus carriage in hemodialysis outpatients: a predictor of worse outcome

vor 13 Jahren
Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy

vor 13 Jahren
Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set

Factors influencing the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a large data set

vor 13 Jahren
Genome-wide linkage analysis of congenital heart defects using MOD score analysis identifies two novel loci

Genome-wide linkage analysis of congenital heart defects using MOD score analysis identifies two novel loci

vor 13 Jahren
Comparison of symptomatic and asymptomatic atherosclerotic carotid plaques using parallel imaging and 3 T black-blood in vivo CMR

Comparison of symptomatic and asymptomatic atherosclerotic carotid plaques using parallel imaging and 3 T black-blood in vivo CMR

vor 13 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Changes in circulating microRNAs after radiochemotherapy in head and neck cancer patients“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz